Market Overview
Global travelers vaccines market size was valued at USD 3.63 billion in 2024. The market is projected to grow from USD 4.01 billion in 2025 to USD 6.77 billion by 2032, exhibiting a CAGR of 9.5% during the forecast period.
Travelers vaccines are specialized biological preparations that provide immunity against diseases prevalent in specific geographical regions. These vaccines typically contain weakened or inactivated pathogens or their components, which stimulate the body's immune system to recognize and combat potential infections. Key vaccine types include those for hepatitis A/B, rabies, typhoid fever, yellow fever, Japanese encephalitis, meningococcal meningitis, and cholera.
USD 3.63 billion in 2024
2032 USD 6.77 billion by 2032
of 9.5%
Hepatitis Vaccines Lead the Market Owing to High Disease Prevalence in Travel
Destinations
The market is segmented based on type into:
Meningococcal Vaccine
Japanese Encephalitis Vaccine
Yellow Fever Vaccine
Hepatitis Vaccine
Subtypes: Hepatitis A, Hepatitis B, and combination vaccines
By Application
Tourists Dominate Demand Due to Increasing International Travel Activities
The market is segmented based on end user into:
Tourists Students Workers Others
Our Key Players
GlaxoSmithKline plc (U.K.)
Sanofi Pasteur (France)
Merck & Co., Inc. (U.S.)
Pfizer Inc. (U.S.)
China National Biotec Group (CNBG) (China)
https://www.24lifesciences.com/dow
https://www.24lifesciences.com
